HSA
CARM

Hussman Strategic Advisors’s Carisma Therapeutics CARM Stock Holding History

Hussman Strategic Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,250
Closed -$22.2K – 234
2023
Q3 		$22.2K Buy
+5,250
New +$33.2K ﹤0.01% 290

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hussman Strategic Advisors's CARM Position: Q4 2023 in Review

Hussman Strategic Advisors sold out of Carisma Therapeutics (CARM) in Q4 2023, closing a stake of 5,250 shares — an estimated $22.2K sold.

Hussman Strategic Advisors first reported a position in CARM in Q3 2023 and held it in 1 quarter. The position peaked at $22.2K in Q3 2023. 50 funds tracked by Wall St. Rank hold CARM as of Q4 2023.

  • Hussman Strategic Advisors reported no remaining Carisma Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Hussman Strategic Advisors sold 5,250 Carisma Therapeutics shares in Q4 2023, an estimated $22.2K.
  • Hussman Strategic Advisors first reported a position in Carisma Therapeutics in Q3 2023 and held it in 1 quarter.
  • Hussman Strategic Advisors's Carisma Therapeutics position peaked at $22.2K in Q3 2023.
  • 50 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2023.

Based on Hussman Strategic Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.